Sign inJoin waitlistJoin the waitlist

JN

Jacklyn Nemunaitis

Physician · University of New Mexico School of Medicine

Credentials: · · · · ·

History

University of New Mexico School of Medicine
2019–Present

Hematology and Medical Oncology
University of New Mexico-Main Campus
2015–2018
Internal Medicine
University of New Mexico School of Medicine
2012–2015
University of Texas Medical Branch at Galveston School of Medicine
2008–2012

Research

Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico
Review · BMC Cancer · 2018 · First of 8 authors · 50 citations
Chronic lymphocytic leukemia with clinical debut as neurological involvement: a rare phenomenon and the need for better predictive markers
Case report · BMC Hematology · 2017 · 7 citations
Developing questions to assess and measure patients' perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
Clinical and Experimental Medicine · 2024 · 1 citations

UG
Ursa Glaberman
4 papers
BT
Bernard Tawfik
3 papers
ZD
Zoneddy Dayao
2 papers
AM
Alex Millhuff
1 paper · 1 as a resident
Alissa Greenbaum
1 paper
AR
Arpit Rao
1 paper · 1 as a fellow
Aymen Baig
1 paper · 1 as a resident
BL
Benny Liem
1 paper
Cecilia Yi
1 paper
Cheryl Willman
1 paper
CH
Cristhiam Hernandez
1 paper
Daniel Bustamante
1 paper · 1 as a fellow

Clinical trials

Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
Principal investigator · Active not recruiting
New Mexico Cancer Research Alliance
2023–2026
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2029
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034